Skip to content
lifestyle.houstonnewstoday.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
LB Pharmaceuticals Inc
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
October 6, 2026
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer
September 15, 2026
LB Pharmaceuticals to Participate in Upcoming September Investor Events
September 3, 2026
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
September 3, 2026
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026
LB Pharmaceuticals Announces $150 Million Private Placement
July 29, 2026
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia
July 22, 2026
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
June 30, 2026
LB Pharmaceuticals to Participate in Upcoming June Investor Events
May 28, 2026
1
2
Next Page
→